BOK Financial Private Wealth’s Charles River Laboratories CRL Stock Holding History

BOK Financial Private Wealth’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13K	Buy	+5	New	+$890	﹤0.01%	689

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BOK Financial Private Wealth's CRL Position: Q2 2026 in Review

BOK Financial Private Wealth opened a new position in Charles River Laboratories (CRL) in Q2 2026: 5 shares worth $1.13K. The stake represents ﹤0.01% of the portfolio and ranks #689 among its holdings.

563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

BOK Financial Private Wealth held 5 shares of Charles River Laboratories worth $1.13K as of Q2 2026.
Charles River Laboratories was a new BOK Financial Private Wealth position in Q2 2026.
Charles River Laboratories made up ﹤0.01% of BOK Financial Private Wealth's portfolio in Q2 2026, its #689 holding.
563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on BOK Financial Private Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.